{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import os\n",
    "import pandas as pd\n",
    "import pyodbc\n",
    "import requests\n",
    "import sqlalchemy\n",
    "from azure.ai.projects import AIProjectClient\n",
    "from azure.ai.projects.models import BingGroundingTool\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import DefaultAzureCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "from dotenv import load_dotenv\n",
    "from openai import AzureOpenAI\n",
    "from rich.console import Console\n",
    "from rich.panel import Panel\n",
    "\n",
    "load_dotenv()\n",
    "console = Console()\n",
    "\n",
    "# Azure OpenAI configuration\n",
    "AZURE_OPENAI_API_KEY = os.getenv(\"AZURE_OPENAI_API_KEY\", \"your-azure-openai-api-key\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\", \"2024-10-21\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_ENDPOINT\", \"https://your-azure-openai-endpoint.openai.azure.com/\")\n",
    "AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME = os.getenv(\"AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME\", \"gpt-4o\")  # update as needed\n",
    "\n",
    "# Azure AI Search configuration\n",
    "AZURE_SEARCH_ENDPOINT = os.getenv(\"AZURE_SEARCH_SERVICE_ENDPOINT\", \"https://your-search-service.search.windows.net\")\n",
    "AZURE_SEARCH_KEY = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\", \"your-azure-search-key\")\n",
    "SEARCH_INDEX_NAME = \"acc-guidelines-index\"\n",
    "\n",
    "# Azure AI Project configuration\n",
    "AZURE_CONNECTION_STRING = os.getenv(\"AZURE_CONNECTION_STRING\", \"your-azure-connection-string\")\n",
    "BING_CONNECTION_NAME = os.getenv(\"BING_CONNECTION_NAME\", \"fsunavalabinggrounding\")\n",
    "\n",
    "# Import Azure libraries for search\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "\n",
    "# Import Azure OpenAI client\n",
    "from openai import AzureOpenAI\n",
    "\n",
    "console = Console()\n",
    "\n",
    "# Azure SQL connection details (for patient data)\n",
    "server = os.getenv(\"AZURE_SQL_SERVER_NAME\")\n",
    "database = os.getenv(\"AZURE_SQL_DATABASE_NAME\")\n",
    "username = os.getenv(\"AZURE_SQL_USER_NAME\")\n",
    "password = os.getenv(\"AZURE_SQL_PASSWORD\")\n",
    "driver = '{ODBC Driver 17 for SQL Server}'\n",
    "\n",
    "# Create an Azure SQL connection string\n",
    "AZURE_SQL_CONNECTION_STRING = f\"DRIVER={driver};SERVER={server};DATABASE={database};UID={username};PWD={password}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize the Azure OpenAI client\n",
    "openai_client = AzureOpenAI(\n",
    "    api_key=AZURE_OPENAI_API_KEY,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "    azure_endpoint=AZURE_OPENAI_ENDPOINT,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "from azure.search.documents import SearchClient\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "\n",
    "def search_acc_guidelines(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the Azure AI Search index 'acc-guidelines-index' \n",
    "    for relevant American College of Cardiology (ACC) guidelines.\n",
    "    \"\"\"\n",
    "    credential = AzureKeyCredential(AZURE_SEARCH_KEY)\n",
    "    client = SearchClient(\n",
    "        endpoint=AZURE_SEARCH_ENDPOINT,\n",
    "        index_name=SEARCH_INDEX_NAME,\n",
    "        credential=credential,\n",
    "    )\n",
    "    \n",
    "    results = client.search(\n",
    "        search_text=query,\n",
    "        vector_queries=[\n",
    "            VectorizableTextQuery(\n",
    "                text=query,\n",
    "                k_nearest_neighbors=10,   # Adjust as needed\n",
    "                fields=\"embedding\"   # Adjust based on your index schema\n",
    "            )\n",
    "        ],\n",
    "        query_type=\"semantic\",\n",
    "        semantic_configuration_name=\"default\",\n",
    "        search_fields=[\"chunk\"],\n",
    "        top=10,\n",
    "        include_total_count=True\n",
    "    )\n",
    "    \n",
    "    retrieved_texts = []\n",
    "    for result in results:\n",
    "        content_chunk = result.get(\"chunk\", \"\")\n",
    "        retrieved_texts.append(content_chunk)\n",
    "    \n",
    "    context_str = \"\\n\".join(retrieved_texts) if retrieved_texts else \"No relevant guidelines found.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: ACC Guidelines Search\\nQuery: {query}\",\n",
    "            style=\"bold yellow\"\n",
    "        )\n",
    "    )\n",
    "    return context_str\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_bing_grounding(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the public web using the Bing Web Grounding Tool via Azure AI Agent Service.\n",
    "    Returns information about recent updates from the web.\n",
    "    \"\"\"\n",
    "    # Create an Azure AI Client\n",
    "    project_client = AIProjectClient.from_connection_string(\n",
    "        credential=DefaultAzureCredential(),\n",
    "        conn_str=AZURE_CONNECTION_STRING,\n",
    "    )\n",
    "    \n",
    "    try:\n",
    "        with project_client:\n",
    "            # Get the Bing connection\n",
    "            bing_connection = project_client.connections.get(\n",
    "                connection_name=BING_CONNECTION_NAME\n",
    "            )\n",
    "            conn_id = bing_connection.id\n",
    "            \n",
    "            # Initialize agent bing tool\n",
    "            bing = BingGroundingTool(connection_id=conn_id)\n",
    "            \n",
    "            # Create agent with the bing tool\n",
    "            agent = project_client.agents.create_agent(\n",
    "                model=\"gpt-4o\", # NOTE, GPT-4o-mini cannot be used with Bing Grounding Tool as of now\n",
    "                name=\"bing-search-agent\",\n",
    "                instructions=f\"Search the web for information about: {query}. Provide a concise but comprehensive summary.\",\n",
    "                tools=bing.definitions,\n",
    "                headers={\"x-ms-enable-preview\": \"true\"}\n",
    "            )\n",
    "            \n",
    "            # Create thread for communication\n",
    "            thread = project_client.agents.create_thread()\n",
    "            \n",
    "            # Create message to thread\n",
    "            project_client.agents.create_message(\n",
    "                thread_id=thread.id,\n",
    "                role=\"user\",\n",
    "                content=query,\n",
    "            )\n",
    "            \n",
    "            # Create and process agent run\n",
    "            run = project_client.agents.create_and_process_run(\n",
    "                thread_id=thread.id, \n",
    "                assistant_id=agent.id\n",
    "            )\n",
    "            \n",
    "            if run.status == \"failed\":\n",
    "                result_text = f\"Bing search failed: {run.last_error}\"\n",
    "            else:\n",
    "                # Fetch messages to get the response\n",
    "                messages = project_client.agents.list_messages(thread_id=thread.id)\n",
    "                # Get the last assistant message\n",
    "                assistant_messages = [m for m in messages.get('data', []) if m.get('role') == 'assistant']\n",
    "                if assistant_messages:\n",
    "                    # Extract the text content from the last assistant message\n",
    "                    content_list = assistant_messages[-1].get('content', [])\n",
    "                    result_text = \"\"\n",
    "                    for content_item in content_list:\n",
    "                        if isinstance(content_item, dict) and 'text' in content_item:\n",
    "                            result_text += content_item.get('text', \"\")\n",
    "                    \n",
    "                    if not result_text:\n",
    "                        result_text = \"No results found.\"\n",
    "                else:\n",
    "                    result_text = \"No results found.\"\n",
    "            \n",
    "            # Clean up resources\n",
    "            project_client.agents.delete_agent(agent.id)\n",
    "            \n",
    "    except Exception as e:\n",
    "        result_text = f\"Bing search failed with error: {str(e)}\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: Bing Grounding Search\\nQuery: {query}\",\n",
    "            style=\"bold magenta\"\n",
    "        )\n",
    "    )\n",
    "    return result_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sqlalchemy\n",
    "\n",
    "def lookup_patient_data(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Queries the 'PatientMedicalData' table in Azure SQL and returns the results as a string.\n",
    "    'query' should be a valid SQL statement.\n",
    "    This version uses SQLAlchemy to create an engine, which is fully supported by pandas.read_sql.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Construct the connection URI for SQLAlchemy\n",
    "        connection_uri = (\n",
    "            f\"mssql+pyodbc://{username}:{password}@{server}/{database}\"\n",
    "            \"?driver=ODBC+Driver+17+for+SQL+Server\"\n",
    "        )\n",
    "        engine = sqlalchemy.create_engine(connection_uri)\n",
    "        \n",
    "        # Use the engine in pandas.read_sql, which avoids the warning\n",
    "        df = pd.read_sql(query, engine)\n",
    "        if df.empty:\n",
    "            return \"No rows found.\"\n",
    "        return df.to_string(index=False)\n",
    "    except Exception as e:\n",
    "        return f\"Database error: {str(e)}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_acc_guidelines\",\n",
    "            \"description\": \"Query the ACC guidelines for official cardiology recommendations. Use keywords related to cardiology conditions, treatments, or guidelines.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Keywords or specific question related to cardiology guidelines.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_bing_grounding\",\n",
    "            \"description\": \"Perform a public web search for real-time or external information using Bing Grounding. For example, 'FDA new hyperlipidemia drugs', 'recent hypertension medication approvals'.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"General query to retrieve public data.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"lookup_patient_data\",\n",
    "            \"description\": (\n",
    "                \"Query Azure SQL PatientMedicalData table. Schema: \"\n",
    "                \"PatientID: INT (PK, Identity), FirstName: VARCHAR(100), LastName: VARCHAR(100), \"\n",
    "                \"DateOfBirth: DATE, Gender: VARCHAR(20), ContactNumber: VARCHAR(100), EmailAddress: VARCHAR(100), \"\n",
    "                \"Address: VARCHAR(255), City: VARCHAR(100), PostalCode: VARCHAR(20), Country: VARCHAR(100), \"\n",
    "                \"MedicalCondition: VARCHAR(255), Medications: VARCHAR(255), Allergies: VARCHAR(255), BloodType: VARCHAR(10), \"\n",
    "                \"LastVisitDate: DATE, SmokingStatus: VARCHAR(50), AlcoholConsumption: VARCHAR(50), ExerciseFrequency: VARCHAR(50), \"\n",
    "                \"Occupation: VARCHAR(100), Height_cm: DECIMAL(5,2), Weight_kg: DECIMAL(5,2), BloodPressure: VARCHAR(20), \"\n",
    "                \"HeartRate_bpm: INT, Temperature_C: DECIMAL(3,1), Notes: VARCHAR(MAX). Use SQL to retrieve patient data.\"\n",
    "            ),\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Valid SQL query for PatientMedicalData table to get patient information.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "]\n",
    "\n",
    "# For convenience, map the tool name to the actual function\n",
    "tool_implementations = {\n",
    "    \"search_acc_guidelines\": search_acc_guidelines,\n",
    "    \"search_bing_grounding\": search_bing_grounding,\n",
    "    \"lookup_patient_data\": lookup_patient_data,\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# System Prompt for the Agent\n",
    "# ----------------------------\n",
    "SYSTEM_PROMPT = (\n",
    "    \"You are a cardiology-focused AI assistant with access to three tools:\\n\"\n",
    "    \"1) 'lookup_patient_data' for querying patient records from Azure SQL.\\n\"\n",
    "    \"2) 'search_acc_guidelines' for official ACC guidelines.\\n\"\n",
    "    \"3) 'search_bing_grounding' for real-time public information using Bing Grounding.\\n\\n\"\n",
    "    \"You can call these tools in any order, multiple times if needed, to gather all the context.\\n\"\n",
    "    \"Stop calling tools only when you have enough information to provide a final, cohesive answer.\\n\"\n",
    "    \"Then output your final answer to the user.\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_multi_step_agent(user_query: str, max_steps: int = 10):\n",
    "    \"\"\"\n",
    "    A multi-step agent with enhanced debugging logs using the new tools syntax.\n",
    "    \"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
    "        {\"role\": \"user\", \"content\": user_query}\n",
    "    ]\n",
    "\n",
    "    for step in range(max_steps):\n",
    "        console.print(Panel(f\"**Step {step+1}**: Starting step {step+1}\", title=\"Step Start\", style=\"bold cyan\"))\n",
    "        \n",
    "        response = openai_client.chat.completions.create(\n",
    "            model=AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME,\n",
    "            messages=messages,\n",
    "            tools=tools,\n",
    "            tool_choice=\"auto\",\n",
    "            max_tokens=8000,\n",
    "        )\n",
    "        response_message = response.choices[0].message\n",
    "        \n",
    "        console.print(Panel(f\"[DEBUG] Step {step+1}: Raw response_message: {response_message}\", title=\"Raw Response\", style=\"dim\"))\n",
    "        \n",
    "        # IMPORTANT: Append the assistant's message (which includes tool_calls) to the conversation.\n",
    "        messages.append(response_message)\n",
    "        \n",
    "        if response_message.tool_calls:\n",
    "            for tool_call in response_message.tool_calls:\n",
    "                function_name = tool_call.function.name\n",
    "                arguments_str = tool_call.function.arguments\n",
    "                \n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool called: {function_name}\", title=\"Tool Call Info\", style=\"bold magenta\"))\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: arguments_str: {arguments_str}\", title=\"Arguments String\", style=\"magenta\"))\n",
    "                \n",
    "                if arguments_str.strip() == \"\":\n",
    "                    function_args = {}\n",
    "                else:\n",
    "                    try:\n",
    "                        function_args = json.loads(arguments_str)\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (JSON parsed): {function_args}\", title=\"Parsed Arguments\", style=\"green\"))\n",
    "                    except json.JSONDecodeError as e:\n",
    "                        function_args = {}\n",
    "                        console.print(\n",
    "                            Panel(\n",
    "                                \"Warning: Could not decode tool call arguments; defaulting to empty dict.\",\n",
    "                                title=\"JSONDecodeError\",\n",
    "                                style=\"bold red\"\n",
    "                            )\n",
    "                        )\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: JSONDecodeError details: {e}\", title=\"JSONDecodeError Detail\", style=\"bold red\"))\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (defaulted): {function_args}\", title=\"Defaulted Arguments\", style=\"red\"))\n",
    "                \n",
    "                # Ensure the 'query' key is present\n",
    "                if \"query\" not in function_args or not function_args[\"query\"]:\n",
    "                    function_args[\"query\"] = user_query\n",
    "                    console.print(Panel(f\"[DEBUG] Step {step+1}: 'query' key defaulted to user_query: {user_query}\", title=\"Defaulted Query Key\", style=\"yellow\"))\n",
    "                \n",
    "                console.print(\n",
    "                    Panel(\n",
    "                        f\"**Step {step+1}**: LLM calls tool [bold]{function_name}[/bold]\\n\\n\"\n",
    "                        f\"**Arguments**:\\n{json.dumps(function_args, indent=2)}\",\n",
    "                        title=\"Tool Call\",\n",
    "                        style=\"bold blue\"\n",
    "                    )\n",
    "                )\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Calling tool implementation: {function_name} with args: {function_args}\", title=\"Tool Implementation Call\", style=\"bold magenta\"))\n",
    "                \n",
    "                tool_fn = tool_implementations.get(function_name)\n",
    "                if tool_fn is None:\n",
    "                    tool_output = f\"[Error] No implementation for tool '{function_name}'.\"\n",
    "                else:\n",
    "                    tool_output = tool_fn(**function_args)\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool output: {tool_output}\", title=\"Tool Output\", style=\"italic blue\"))\n",
    "                \n",
    "                # Format the tool response message correctly\n",
    "                messages.append({\n",
    "                    \"tool_call_id\": tool_call.id,\n",
    "                    \"role\": \"tool\",\n",
    "                    \"name\": function_name,\n",
    "                    \"content\": str(tool_output),  # Simple string for tool response\n",
    "                })\n",
    "        else:\n",
    "            final_answer = response_message.content\n",
    "            console.print(\n",
    "                Panel(\n",
    "                    final_answer,\n",
    "                    title=\"Final Answer\",\n",
    "                    style=\"bold green\",\n",
    "                    border_style=\"yellow\"\n",
    "                )\n",
    "            )\n",
    "            return\n",
    "\n",
    "    console.print(\n",
    "        Panel(\n",
    "            \"Max steps reached without a final answer. Stopping.\",\n",
    "            title=\"Warning\",\n",
    "            style=\"bold red\"\n",
    "        )\n",
    "    )\n",
    "    return"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "user_question_1 = \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\n",
    "run_multi_step_agent(user_question_1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_6MZOy0swXzfkdykAQdLAcMcK',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"recent FDA updates 2025 new anticoagulant therapies\"}',                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_bing_grounding'), type='function')])                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_6MZOy0swXzfkdykAQdLAcMcK', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"recent FDA updates 2025 new anticoagulant therapies\"}', \u001b[0m\u001b[2m                \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_bing_grounding                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_bing_grounding\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\":\"recent FDA updates 2025 new anticoagulant therapies\"}                  │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\":\"recent FDA updates 2025 new anticoagulant therapies\"}\u001b[0m\u001b[35m                 \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'recent FDA updates 2025 new anticoagulant therapies'}   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'recent FDA updates 2025 new anticoagulant therapies'}\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"recent FDA updates 2025 new anticoagulant therapies\"                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"recent FDA updates 2025 new anticoagulant therapies\"\u001b[0m\u001b[1;34m                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'recent FDA updates     │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ 2025 new anticoagulant therapies'}                                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'recent FDA updates \u001b[0m\u001b[1;35m   \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m2025 new anticoagulant therapies'}\u001b[0m\u001b[1;35m                                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Tool Invoked: Bing Grounding Search                                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Query: recent FDA updates 2025 new anticoagulant therapies                                                      │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mTool Invoked: Bing Grounding Search\u001b[0m\u001b[1;35m                                                                            \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mQuery: recent FDA updates 2025 new anticoagulant therapies\u001b[0m\u001b[1;35m                                                     \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: No results found.                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: No results found.\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='It appears that there are no recent        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ updates available regarding new anticoagulant therapies from the FDA for the year 2025. If you have any other   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ questions or need information on a different topic, feel free to ask!', refusal=None, role='assistant',         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=None)                                                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='It appears that there are no recent \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mupdates available regarding new anticoagulant therapies from the FDA for the year 2025. If you have any other \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mquestions or need information on a different topic, feel free to ask!', refusal=None, role='assistant', \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> It appears that there are no recent updates available regarding new anticoagulant therapies from the FDA for    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> the year 2025. If you have any other questions or need information on a different topic, feel free to ask!      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mIt appears that there are no recent updates available regarding new anticoagulant therapies from the FDA for \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mthe year 2025. If you have any other questions or need information on a different topic, feel free to ask!\u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_2 = \"Are there any recent updates in 2025 on new anticoagulant therapies from the FDA?\"\n",
    "run_multi_step_agent(user_question_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_3jvvxYVrfclRVZGqb1RYiYaZ',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ MedicalCondition LIKE \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ type='function')])                                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_3jvvxYVrfclRVZGqb1RYiYaZ', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMedicalCondition LIKE \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'),\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtype='function')])\u001b[0m\u001b[2m                                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: lookup_patient_data                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: lookup_patient_data\u001b[0m\u001b[1;35m                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE          │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}                                    │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE \u001b[0m\u001b[35m        \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35mMedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}\u001b[0m\u001b[35m                                   \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mWHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[1;34m               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m'%Hypertension%' AND Medications LIKE '%Lisinopril%'\"\u001b[0m\u001b[1;34m                                                          \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT COUNT(*) as       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE          │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ '%Lisinopril%'\"}                                                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT COUNT(*) as \u001b[0m\u001b[1;35m     \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mPatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE \u001b[0m\u001b[1;35m        \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m'%Lisinopril%'\"}\u001b[0m\u001b[1;35m                                                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output:  PatientCount                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│          1071                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output:  PatientCount\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m         1071\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='There are 1,071 patients who have          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hypertension and are prescribed Lisinopril.', refusal=None, role='assistant', audio=None, function_call=None,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=None)                                                                                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='There are 1,071 patients who have \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHypertension and are prescribed Lisinopril.', refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=None)\u001b[0m\u001b[2m                                                                                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> There are 1,071 patients who have Hypertension and are prescribed Lisinopril.                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThere are 1,071 patients who have Hypertension and are prescribed Lisinopril.\u001b[0m\u001b[1;32m                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_3 = \"How many patients have Hypertension and are prescribed Lisinopril?\"\n",
    "# The agent should generate a valid SQL query, for example:\n",
    "## Note, the answer will depend on the actual data in the database (it should return 1071!)\n",
    "run_multi_step_agent(user_question_3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_ViHLoJK7yi3Nz3aCxYyjHKUj',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_7qzkRLDvYRxrMasxANimdOvF', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"hyperlipidemia treatment guidelines\"}', name='search_acc_guidelines'), type='function'),                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_B697x4mdQVTvLDVqFskxY6cs', function=Function(arguments='{\"query\": \"FDA   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medication updates hyperlipidemia February 2025\"}', name='search_bing_grounding'), type='function')])           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_ViHLoJK7yi3Nz3aCxYyjHKUj', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_7qzkRLDvYRxrMasxANimdOvF', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"hyperlipidemia treatment guidelines\"}', name='search_acc_guidelines'), type='function'), \u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_B697x4mdQVTvLDVqFskxY6cs', function=Function(arguments='{\"query\": \"FDA \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedication updates hyperlipidemia February 2025\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: lookup_patient_data                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: lookup_patient_data\u001b[0m\u001b[1;35m                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND         │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ LastName='Paul'\"}                                                                                               │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND \u001b[0m\u001b[35m       \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35mLastName='Paul'\"}\u001b[0m\u001b[35m                                                                                              \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ FirstName='Gloria' AND LastName='Paul'\"}                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE \u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mFirstName='Gloria' AND LastName='Paul'\"}\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"\u001b[0m\u001b[1;34m                     \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM            │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"}                                               │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM \u001b[0m\u001b[1;35m          \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mPatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"}\u001b[0m\u001b[1;35m                                              \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Notes                                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│          1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ year parent. Happen energy level anyone position. Few available thought world development.                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNotes\u001b[0m\u001b[3;34m                                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34myear parent. Happen energy level anyone position. Few available thought world development.\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_acc_guidelines                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_acc_guidelines\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia treatment guidelines\"}                                 │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia treatment guidelines\"}\u001b[0m\u001b[35m                                \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia treatment guidelines'}                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia treatment guidelines'}\u001b[0m\u001b[32m                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"hyperlipidemia treatment guidelines\"                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"hyperlipidemia treatment guidelines\"\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia         │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ treatment guidelines'}                                                                                          │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia \u001b[0m\u001b[1;35m       \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mtreatment guidelines'}\u001b[0m\u001b[1;35m                                                                                         \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: hyperlipidemia treatment guidelines                                                                      │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: hyperlipidemia treatment guidelines\u001b[0m\u001b[1;33m                                                                     \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ severity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cerebral Ischemia Databank) studies, respectively (258).                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS I                                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Evidence: B)                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS IIa                                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259).  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Level of Evidence: B)                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ among those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (261–264). (Level of Evidence: B)                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reasonable (261,263,265). (Level of Evidence: B)                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Trial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ involving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (267). In the ARIC study, the relationships between lipid values and incident ischemic.                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e299                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy. The same reasoning holds for any patient whose LDL-C level remains $70 mg/dL ($1.8 mmol/L) on          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ maximally tolerated statin therapy.                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.2. Severe Hypercholesterolemia (LDL-C ‡190 mg/dL [‡4.9 mmol/L])                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Primary Severe Hypercholesterolemia (LDL-C $190 mg/dL [$4.9 mmol/L])                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 9 and 10.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) maximally     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tolerated statin therapy is recommended (S4.2-1—S4.2-7).|                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) who achieve │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ level of 100 mg/dL or higher (‡2.6 mmol/L) ezetimibe therapy is reasonable (S4.2-8—S4.2-10).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|B-R|In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dL or higher (‡4.9 mmol/L), who   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (£3.4       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be considered (S4.2-11, S4.2-12).|                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|B-R|In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (‡2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be considered (S4.2-9, S4.2-13—S4.2-15).|                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|C-LD|In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL or higher (‡5.7 mmol/L)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and who achieve an on-treatment LDL-C level of 130 mg/dL or higher (‡3.4 mmol/L) while receiving maximally      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (S4.2-13—S4.2-17).| │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Value Statement: Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and ezetimibe therapy, PCSK9 inhibitors provide uncertain value at mid-2018 U.S. list prices.                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Patients with severe hypercholesterolemia have a high lifetime risk, and decisions about statins in these       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ patients do not require ASCVD risk scoring. These patients derive net ASCVD risk reduction benefit from         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ interventions that increase expression of LDL receptors. The strongest data have been derived from statin RCTs, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ which have demonstrated greater risk reduction with statins than with moderate-intensity statin therapy.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Ezetimibe plus a moderate-intensity statin is associated with greater LDL-C reduction than is statin            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ monotherapy in patients with heterozygous FH, and the combination reduces ASCVD risk more than                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ moderate-intensity statin monotherapy in patients who have had a recent ACS.                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e300 Grundy et al.                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be indicated.                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ both primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ administered to patients with primary severe hypercholesterolemia.                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ greater in the combined-therapy group, but there was no difference in carotid intima-media thickness between    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ placebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ showed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ than that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ indicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ characteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50%  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C lowering (S4.2-9).                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. PCSK9 inhibitors are promising drugs for treatment of FH                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e318                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al.                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.2. Hypertriglyceridemia                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Hypertriglyceridemia                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ nephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ higher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consider a persistently elevated triglyceride level as a factor favoring initiation or intensification of       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ causes of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.5.2-9).|                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Two categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ acute pancreatitis. Therapies should address excesses in both lipoproteins.                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ associated risk factors by nonpharmacological means where possible. This can best be achieved by identification │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tamoxifen, raloxifene, retinoids,                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 73, N O . 2 4 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e313                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ As discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.).                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4).         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Secondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ addressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ A smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ present. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ suggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ starting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ have been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ individuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ One approach to identifying young adults who could benefit from statins or drug combination would be to detect  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Children and Adolescents                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-1—S4.4.4.3-4).|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3,                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L .  7 3 , N O . 2 4 , 2 0 1 9                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al.  e295                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ They generally are well tolerated, but long-term safety remains to be proven (S3.2.2-4—S3.2.2-6). Two           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ categories of triglyceride-lowering drugs, niacin and fibrates, may also mildly lower LDL-C levels in patients  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with normal triglycerides. They may be useful in some patients with severe hypertriglyceridemia, but in the     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ present document they are not listed as LDL-lowering drugs. See Table S4 in the Web Supplement.                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 3.2.3. Nonstatin Add-on Drugs to Statin Therapy                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Under certain circumstances, nonstatin medications (ezetimibe, bile acid sequestrants, and PCSK9 inhibitors)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be useful in combination with statin therapy. The addition of a bile acid sequestrant or ezetimibe to a     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin regimen increases the magnitude of LDL-C lowering by approximately 15% to 30% and 13% to 20%,            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ respectively (S3.2.3-1, S3.2.3-2). The addition of a PCSK9 inhibitor to a statin regimen has been shown to      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ further reduce LDL-C levels by 43% to 64% (S3.2.3-3, S3.2.3-4). See Table S5 in the Web Supplement.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4. PATIENT MANAGEMENT GROUPS                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.1. Secondary ASCVD Prevention                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Recommendations for Statin Therapy Use in Patients With ASCVD Referenced studies that support recommendations   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ are summarized in Online Data Supplements 6 to 8 and in the Systematic Review Report.                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|A|In patients who are 75 years of age or younger with clinical ASCVD,* high-intensity statin therapy should  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.1-1—S4.1-5).|                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|A|In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of achieving a 30% to 49% reduction in LDL-C levels (S4.1-3, S4.1-6—S4.1-13).|                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In patients with clinical ASCVD who are judged to be very high risk and considered for PCSK9 inhibitor  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy, maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ezetimibe (S4.1-14, S4.1-15).|                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa| |In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C lowering therapy with LDL-C 70 mg/dL or higher (≥1.8 mmol/L) or a non–HDL-C level of 100 mg/dL or higher  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (≥2.6 mmol/L) it is reasonable to add a PCSK9 inhibitor following a clinician–patient discussion about the net  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ benefit, safety, and cost (S4.1-15—S4.1-19).|                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In patients with clinical ASCVD who are on maximally tolerated statin therapy and are judged to be at  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ very high risk and have an LDL-C level of 70 mg/dL or higher (≥1.8 mmol/L) it is reasonable to add ezetimibe    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy (S4.1-14, S4.1-15).|                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Low Value (LOE: B-NR)| |At mid-2018 list prices, PCSK9 inhibitors have a low cost value (&gt;$150,000 per QALY)   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ compared to good cost value (&lt;$50,000 per QALY) (Section 7 provides a full discussion of the dynamic            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ interaction of different prices and clinical benefit) (S4.1-20—S4.1-22).|                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In patients                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.2. Lipid Measurement                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Modest differences in LDL-C levels associated with the postprandial state, use of a nonfasting sample is        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ effective to document baseline lipid levels before initiation of statin therapy in individuals with clinical    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD (S2.2-1—S2.2-6). In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lipid profile is reasonable for initial evaluation.                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Given relatively modest differences in LDL-C levels between fasting and non-fasting samples, the latter is   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ generally adequate to document baseline lipid levels prior to initiation of statin therapy (S2.2-1—S2.2-6).     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. The unreliability of the Friedewald-calculated LDL-C levels rises at lower levels of LDL-C, particularly &lt;70 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg/dL (&lt;1.8 mmol/L). If accurate measurements of LDL-C levels are needed at very low LDL-C, calculation         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ adjustments can be used (S2.2-7—S2.2-9). Measurement of apoB may be useful in determining whether               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemia is an atherogenic condition (S2.2-12, S2.2-13).                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile is     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reasonable for initial evaluation to aid in the understanding and identification of familial lipid disorders    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S2.2-12, S2.2-13).                                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.3. Measurements of Apolipoprotein B and Lipoprotein (a)                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Two lipoprotein entities related to LDL-C are apoB and lipoprotein (a) [Lp(a)]. Because apoB is the major       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ apolipoprotein embedded in LDL and VLDL, several investigators identify strength of association between apoB    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and ASCVD (S2.3-1). Others report a high correlation between apoB and non–HDL-C (S2.3-2). Under certain         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ circumstances, particularly in patients with hypertriglyceridemia, the measurement of apoB may have advantages  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S2.3-3). Nevertheless, apoB measurement carries extra expense, and its measurement in some laboratories may    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ not be reliable (S2.3-4). A relative indication for its measurement would be triglyceride $200 mg/dL. A level   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ &gt;130 mg/dL corresponds to an LDL-C level $160 mg/dL and constitutes a risk-enhancing factor. A persistent       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevation of apoB can be considered a risk-enhancing factor. Separately, Lp(a) is a modified form of LDL that   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ appears to possess atherogenic potential (S2.3-5). Relative indications for its measurement are family history  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of premature ASCVD or personal history of ASCVD not explained by major risk factors. Lp(a) increases ASCVD risk │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially at higher levels. Thus, if a decision is made to measure Lp(a), an Lp(a) $50 mg/dL or $125 nmol/L,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Lp(a) may be considered a risk-enhancing factor (S2.3-6). Current evidence shows that it should be considered   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prediction in adult women in a large clinical trial was minimal (S2.3-7). In the present document, an elevation │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of Lp(a) is considered to be a risk-enhancing factor (S2.3-6). This is especially in those with higher Lp(a)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ values and, if used in women, only in the presence of hypercholesterolemia (S2.3-7).                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.4. Monitoring Response of LDL-C to Statin Therapy                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In large RCTs of cholesterol-lowering therapy, LDL-C lowering has been consistently shown to reduce the risk of │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD. One large meta-analysis (S2.4-1) of statin clinical trials showed a progressive reduction in risk of     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ major ASCVD events with lower on-treatment LDL-C levels. In another larger meta-analysis (S2.4-2) of 14 statin  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ trials, it was observed that a 38.7-mg/dL (1-mmol/L) reduction of LDL-C levels is accompanied by a 21%          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in ASCVD risk. In clinical practice, however, absolute responses in LDL-C to statin therapy depend on │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ baseline                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ it is reasonable to reduce both atherogenic VLDL and associated risk factors by nonpharmacological means where  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ possible. This can best be achieved by identification and treatment of the multiple underlying causes of        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated triglycerides (e.g., lifestyle causes, secondary disorders, and triglyceride-raising drugs)            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.5.2-1). Triglyceride-raising drugs include oral estrogens, tamoxifen, raloxifene, retinoids,                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ immunosuppressive drugs (cyclosporine, sirolimus, tacrolimus), beta blockers, interferon, atypical              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ antipsychotic drugs, protease inhibitors, thiazide diuretics, glucocorticoids, rosiglitazone, bile acid         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ sequestrants, L-asparaginase, and cyclophosphamide.                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. Most patients with severe hypertriglyceridemia have multiple ASCVD risk factors and are at enhanced risk of  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ developing atherosclerotic disease (S4.5.2-3—S4.5.2-5, S4.5.2-9). This risk is conveyed by atherogenic VLDL     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ plus other factors, such as obesity, metabolic syndrome, and hyperglycemia. Although chylomicronemia per se may │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ not be atherogenic, in most patients it associates with other atherogenic factors (S4.5.2-10—S4.5.2-13). For    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ this reason, initiation of statin therapy is reasonable. We stress that statins alone cannot prevent increasing │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ levels of triglycerides in the face of secondary causes (see Recommendation 1) from triggering acute            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemic pancreatitis. Indeed, in the pregnant woman with severe hypertriglyceridemia, statins are  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ not part of the treatment regimen because they are not recommended at the present time in pregnancy. (See       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Section 5., “Statin Safety and Statin-Associated Side Effects.)                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. Epidemiological studies show that patients with moderate hypertriglyceridemia generally are at increased     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ risk of ASCVD (S4.5.2-2—S4.5.2-4). Few studies that primarily recruited patients with hypertriglyceridemia have │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been carried out with triglyceride-lowering drugs. Statin therapy reduces VLDL similarly to fibrates.           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of severe hypertriglyceridemic pregnancy is also beyond the scope of the present guideline and requires         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consultation with an experienced lipid specialist.                                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.4. Adults With CKD                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Adults With CKD                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 36 to 38.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 mmol/L) who are at 10-year      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD risk of 7.5% or higher, CKD not treated with dialysis or kidney transplantation is a risk-enhancing       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ factor and initiation of a moderate-intensity statin or moderate-intensity statins combined with ezetimibe can  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ be useful (S4.5.4-1, S4.5.4-2).|                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|C-LD|In adults with advanced kidney disease that requires dialysis treatment who are currently on          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-lowering therapy with a statin, it may be reasonable to continue the statin (S4.5.4-2).|                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |III: No Benefit|B-R|In adults with advanced kidney disease who require dialysis treatment, initiation of a     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin is not recommended (S4.5.4-3, S4.5.4-4).|                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol.    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2006;98:768–73.                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.1-39                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ George MD, McGill NK, Baker JF. Creatine kinase in the U.S. population: Impact of demographics, comorbidities,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and body composition on the normal range. Medicine (Baltimore). 2016;95:e4344.                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.2. Hypertriglyceridemia                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-1                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-2                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cardiovasc Risk. 1996;3:213–9.                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-3                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ heart disease, and death in men and women. Jama. 2007;298:299–308.                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-4                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ general population. Jama. 2008;300:2142–52.                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-5                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cardiol. 2016;117:1444–8.                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-6                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ trials. Lancet. 2012;380:581–90.                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-7                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol.       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2012;6:450–61.                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-8                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147–50.                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-9                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutrition therapy is the essential cornerstone for       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ effective treatment of “refractory” severe hypertriglyceridemia regardless of pharmaceutical treatment:         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ evidence from a lipid management program. J Clin Lipidol. 2015;9:559–67.                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-10                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families. │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Ann Intern Med. 1977;87:526–34.                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-11                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Steiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V hyperlipoproteinemia. Can    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Med Assoc J. 1971;105:1172–4.                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-12                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovascular mortality in treated patients with severe │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridaemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618–23.                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # S4.5.2-13                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Christian JB, Arondekar B, Buysman EK, et al.                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mseverity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCerebral Ischemia Databank) studies, respectively (258).\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS I\u001b[0m\u001b[3;34m                                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEvidence: B)\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS IIa\u001b[0m\u001b[3;34m                                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mamong those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(261–264). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreasonable (261,263,265). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTrial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minvolving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(267). In the ARIC study, the relationships between lipid values and incident ischemic.\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e299\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy. The same reasoning holds for any patient whose LDL-C level remains $70 mg/dL ($1.8 mmol/L) on \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmaximally tolerated statin therapy.\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.2. Severe Hypercholesterolemia (LDL-C ‡190 mg/dL [‡4.9 mmol/L])\u001b[0m\u001b[3;34m                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Primary Severe Hypercholesterolemia (LDL-C $190 mg/dL [$4.9 mmol/L])\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 9 and 10.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) maximally \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtolerated statin therapy is recommended (S4.2-1—S4.2-7).|\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) who achieve\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mless than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlevel of 100 mg/dL or higher (‡2.6 mmol/L) ezetimibe therapy is reasonable (S4.2-8—S4.2-10).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|B-R|In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dL or higher (‡4.9 mmol/L), who \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (£3.4 \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be considered (S4.2-11, S4.2-12).|\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|B-R|In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(‡2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be considered (S4.2-9, S4.2-13—S4.2-15).|\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|C-LD|In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL or higher (‡5.7 mmol/L) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand who achieve an on-treatment LDL-C level of 130 mg/dL or higher (‡3.4 mmol/L) while receiving maximally \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (S4.2-13—S4.2-17).|\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mValue Statement: Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand ezetimibe therapy, PCSK9 inhibitors provide uncertain value at mid-2018 U.S. list prices.\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mPatients with severe hypercholesterolemia have a high lifetime risk, and decisions about statins in these \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpatients do not require ASCVD risk scoring. These patients derive net ASCVD risk reduction benefit from \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minterventions that increase expression of LDL receptors. The strongest data have been derived from statin RCTs,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwhich have demonstrated greater risk reduction with statins than with moderate-intensity statin therapy. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEzetimibe plus a moderate-intensity statin is associated with greater LDL-C reduction than is statin \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmonotherapy in patients with heterozygous FH, and the combination reduces ASCVD risk more than \u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmoderate-intensity statin monotherapy in patients who have had a recent ACS.\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e300 Grundy et al.\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be indicated.\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthose receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mboth primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madministered to patients with primary severe hypercholesterolemia.\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgreater in the combined-therapy group, but there was no difference in carotid intima-media thickness between \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mplacebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mshowed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthan that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcharacteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve <50% \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6 \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C lowering (S4.2-9).\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. PCSK9 inhibitors are promising drugs for treatment of FH\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e318\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al.\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.2. Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.\u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsider a persistently elevated triglyceride level as a factor favoring initiation or intensification of \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|\u001b[0m\u001b[3;34m                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcauses of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.5.2-9).|\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTwo categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34macute pancreatitis. Therapies should address excesses in both lipoproteins.\u001b[0m\u001b[3;34m                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34massociated risk factors by nonpharmacological means where possible. This can best be achieved by identification\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtamoxifen, raloxifene, retinoids,\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e313\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAs discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.).\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSecondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34maddressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mA smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpresent. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstarting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34midentified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhave been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindividuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).\u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mOne approach to identifying young adults who could benefit from statins or drug combination would be to detect \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msignificant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Children and Adolescents\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle therapy, including moderate caloric restriction and regular aerobic physical activity \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C (S4.4.4.3-1—S4.4.4.3-3,\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L .  7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al.  e295\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThey generally are well tolerated, but long-term safety remains to be proven (S3.2.2-4—S3.2.2-6). Two \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcategories of triglyceride-lowering drugs, niacin and fibrates, may also mildly lower LDL-C levels in patients \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith normal triglycerides. They may be useful in some patients with severe hypertriglyceridemia, but in the \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpresent document they are not listed as LDL-lowering drugs. See Table S4 in the Web Supplement.\u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 3.2.3. Nonstatin Add-on Drugs to Statin Therapy\u001b[0m\u001b[3;34m                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mUnder certain circumstances, nonstatin medications (ezetimibe, bile acid sequestrants, and PCSK9 inhibitors) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be useful in combination with statin therapy. The addition of a bile acid sequestrant or ezetimibe to a \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin regimen increases the magnitude of LDL-C lowering by approximately 15% to 30% and 13% to 20%, \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrespectively (S3.2.3-1, S3.2.3-2). The addition of a PCSK9 inhibitor to a statin regimen has been shown to \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfurther reduce LDL-C levels by 43% to 64% (S3.2.3-3, S3.2.3-4). See Table S5 in the Web Supplement.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4. PATIENT MANAGEMENT GROUPS\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.1. Secondary ASCVD Prevention\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mRecommendations for Statin Therapy Use in Patients With ASCVD Referenced studies that support recommendations \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mare summarized in Online Data Supplements 6 to 8 and in the Systematic Review Report.\u001b[0m\u001b[3;34m                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|A|In patients who are 75 years of age or younger with clinical ASCVD,* high-intensity statin therapy should \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbe initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels \u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.1-1—S4.1-5).|\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|A|In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof achieving a 30% to 49% reduction in LDL-C levels (S4.1-3, S4.1-6—S4.1-13).|\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In patients with clinical ASCVD who are judged to be very high risk and considered for PCSK9 inhibitor \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy, maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mezetimibe (S4.1-14, S4.1-15).|\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa| |In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C lowering therapy with LDL-C 70 mg/dL or higher (≥1.8 mmol/L) or a non–HDL-C level of 100 mg/dL or higher \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(≥2.6 mmol/L) it is reasonable to add a PCSK9 inhibitor following a clinician–patient discussion about the net \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbenefit, safety, and cost (S4.1-15—S4.1-19).|\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In patients with clinical ASCVD who are on maximally tolerated statin therapy and are judged to be at \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mvery high risk and have an LDL-C level of 70 mg/dL or higher (≥1.8 mmol/L) it is reasonable to add ezetimibe \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy (S4.1-14, S4.1-15).|\u001b[0m\u001b[3;34m                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Low Value (LOE: B-NR)| |At mid-2018 list prices, PCSK9 inhibitors have a low cost value (>$150,000 per QALY) \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcompared to good cost value (<$50,000 per QALY) (Section 7 provides a full discussion of the dynamic \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minteraction of different prices and clinical benefit) (S4.1-20—S4.1-22).|\u001b[0m\u001b[3;34m                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In patients\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.2. Lipid Measurement\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mModest differences in LDL-C levels associated with the postprandial state, use of a nonfasting sample is \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34meffective to document baseline lipid levels before initiation of statin therapy in individuals with clinical \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD (S2.2-1—S2.2-6). In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlipid profile is reasonable for initial evaluation.\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Given relatively modest differences in LDL-C levels between fasting and non-fasting samples, the latter is \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenerally adequate to document baseline lipid levels prior to initiation of statin therapy (S2.2-1—S2.2-6).\u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. The unreliability of the Friedewald-calculated LDL-C levels rises at lower levels of LDL-C, particularly <70\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg/dL (<1.8 mmol/L). If accurate measurements of LDL-C levels are needed at very low LDL-C, calculation \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madjustments can be used (S2.2-7—S2.2-9). Measurement of apoB may be useful in determining whether \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemia is an atherogenic condition (S2.2-12, S2.2-13).\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile is \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreasonable for initial evaluation to aid in the understanding and identification of familial lipid disorders \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S2.2-12, S2.2-13).\u001b[0m\u001b[3;34m                                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.3. Measurements of Apolipoprotein B and Lipoprotein (a)\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTwo lipoprotein entities related to LDL-C are apoB and lipoprotein (a) [Lp(a)]. Because apoB is the major \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mapolipoprotein embedded in LDL and VLDL, several investigators identify strength of association between apoB \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand ASCVD (S2.3-1). Others report a high correlation between apoB and non–HDL-C (S2.3-2). Under certain \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcircumstances, particularly in patients with hypertriglyceridemia, the measurement of apoB may have advantages \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S2.3-3). Nevertheless, apoB measurement carries extra expense, and its measurement in some laboratories may \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnot be reliable (S2.3-4). A relative indication for its measurement would be triglyceride $200 mg/dL. A level \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m>130 mg/dL corresponds to an LDL-C level $160 mg/dL and constitutes a risk-enhancing factor. A persistent \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevation of apoB can be considered a risk-enhancing factor. Separately, Lp(a) is a modified form of LDL that \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mappears to possess atherogenic potential (S2.3-5). Relative indications for its measurement are family history \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof premature ASCVD or personal history of ASCVD not explained by major risk factors. Lp(a) increases ASCVD risk\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially at higher levels. Thus, if a decision is made to measure Lp(a), an Lp(a) $50 mg/dL or $125 nmol/L, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLp(a) may be considered a risk-enhancing factor (S2.3-6). Current evidence shows that it should be considered \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprediction in adult women in a large clinical trial was minimal (S2.3-7). In the present document, an elevation\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof Lp(a) is considered to be a risk-enhancing factor (S2.3-6). This is especially in those with higher Lp(a) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mvalues and, if used in women, only in the presence of hypercholesterolemia (S2.3-7).\u001b[0m\u001b[3;34m                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.4. Monitoring Response of LDL-C to Statin Therapy\u001b[0m\u001b[3;34m                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn large RCTs of cholesterol-lowering therapy, LDL-C lowering has been consistently shown to reduce the risk of\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD. One large meta-analysis (S2.4-1) of statin clinical trials showed a progressive reduction in risk of \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmajor ASCVD events with lower on-treatment LDL-C levels. In another larger meta-analysis (S2.4-2) of 14 statin \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtrials, it was observed that a 38.7-mg/dL (1-mmol/L) reduction of LDL-C levels is accompanied by a 21% \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in ASCVD risk. In clinical practice, however, absolute responses in LDL-C to statin therapy depend on\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbaseline\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mit is reasonable to reduce both atherogenic VLDL and associated risk factors by nonpharmacological means where \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpossible. This can best be achieved by identification and treatment of the multiple underlying causes of \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated triglycerides (e.g., lifestyle causes, secondary disorders, and triglyceride-raising drugs) \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.5.2-1). Triglyceride-raising drugs include oral estrogens, tamoxifen, raloxifene, retinoids, \u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mimmunosuppressive drugs (cyclosporine, sirolimus, tacrolimus), beta blockers, interferon, atypical \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mantipsychotic drugs, protease inhibitors, thiazide diuretics, glucocorticoids, rosiglitazone, bile acid \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msequestrants, L-asparaginase, and cyclophosphamide.\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. Most patients with severe hypertriglyceridemia have multiple ASCVD risk factors and are at enhanced risk of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdeveloping atherosclerotic disease (S4.5.2-3—S4.5.2-5, S4.5.2-9). This risk is conveyed by atherogenic VLDL \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mplus other factors, such as obesity, metabolic syndrome, and hyperglycemia. Although chylomicronemia per se may\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnot be atherogenic, in most patients it associates with other atherogenic factors (S4.5.2-10—S4.5.2-13). For \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthis reason, initiation of statin therapy is reasonable. We stress that statins alone cannot prevent increasing\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlevels of triglycerides in the face of secondary causes (see Recommendation 1) from triggering acute \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemic pancreatitis. Indeed, in the pregnant woman with severe hypertriglyceridemia, statins are \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnot part of the treatment regimen because they are not recommended at the present time in pregnancy. (See \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSection 5., “Statin Safety and Statin-Associated Side Effects.)\u001b[0m\u001b[3;34m                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. Epidemiological studies show that patients with moderate hypertriglyceridemia generally are at increased \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrisk of ASCVD (S4.5.2-2—S4.5.2-4). Few studies that primarily recruited patients with hypertriglyceridemia have\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen carried out with triglyceride-lowering drugs. Statin therapy reduces VLDL similarly to fibrates.\u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof severe hypertriglyceridemic pregnancy is also beyond the scope of the present guideline and requires \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsultation with an experienced lipid specialist.\u001b[0m\u001b[3;34m                                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.4. Adults With CKD\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Adults With CKD\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 36 to 38.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 mmol/L) who are at 10-year \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD risk of 7.5% or higher, CKD not treated with dialysis or kidney transplantation is a risk-enhancing \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfactor and initiation of a moderate-intensity statin or moderate-intensity statins combined with ezetimibe can \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbe useful (S4.5.4-1, S4.5.4-2).|\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|C-LD|In adults with advanced kidney disease that requires dialysis treatment who are currently on \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-lowering therapy with a statin, it may be reasonable to continue the statin (S4.5.4-2).|\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|III: No Benefit|B-R|In adults with advanced kidney disease who require dialysis treatment, initiation of a \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin is not recommended (S4.5.4-3, S4.5.4-4).|\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mversus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2006;98:768–73.\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.1-39\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGeorge MD, McGill NK, Baker JF. Creatine kinase in the U.S. population: Impact of demographics, comorbidities, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand body composition on the normal range. Medicine (Baltimore). 2016;95:e4344.\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.2. Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-1\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHeart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.\u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-2\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigh-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCardiovasc Risk. 1996;3:213–9.\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-3\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mheart disease, and death in men and women. Jama. 2007;298:299–308.\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-4\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mFreiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgeneral population. Jama. 2008;300:2142–52.\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-5\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mKarlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlow-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCardiol. 2016;117:1444–8.\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-6\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtrials. Lancet. 2012;380:581–90.\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-7\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mChristian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2012;6:450–61.\u001b[0m\u001b[3;34m                                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-8\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mDuane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147–50.\u001b[0m\u001b[3;34m                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-9\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mRhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutrition therapy is the essential cornerstone for \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34meffective treatment of “refractory” severe hypertriglyceridemia regardless of pharmaceutical treatment: \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mevidence from a lipid management program. J Clin Lipidol. 2015;9:559–67.\u001b[0m\u001b[3;34m                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-10\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGreenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAnn Intern Med. 1977;87:526–34.\u001b[0m\u001b[3;34m                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-11\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSteiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V hyperlipoproteinemia. Can \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mMed Assoc J. 1971;105:1172–4.\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-12\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNeil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovascular mortality in treated patients with severe\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridaemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618–23.\u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# S4.5.2-13\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mChristian JB, Arondekar B, Buysman EK, et al.\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_bing_grounding                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_bing_grounding\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"FDA medication updates hyperlipidemia February 2025\"}                 │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"FDA medication updates hyperlipidemia February 2025\"}\u001b[0m\u001b[35m                \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA medication updates hyperlipidemia February 2025'}   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA medication updates hyperlipidemia February 2025'}\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"FDA medication updates hyperlipidemia February 2025\"                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"FDA medication updates hyperlipidemia February 2025\"\u001b[0m\u001b[1;34m                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'FDA medication updates │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ hyperlipidemia February 2025'}                                                                                  │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'FDA medication updates\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mhyperlipidemia February 2025'}\u001b[0m\u001b[1;35m                                                                                 \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Tool Invoked: Bing Grounding Search                                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Query: FDA medication updates hyperlipidemia February 2025                                                      │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mTool Invoked: Bing Grounding Search\u001b[0m\u001b[1;35m                                                                            \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mQuery: FDA medication updates hyperlipidemia February 2025\u001b[0m\u001b[1;35m                                                     \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: No results found.                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: No results found.\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='### Summary of Findings for Gloria         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Paul:\\n\\n1. **Patient Medical Details:**\\n   - **Name:** Gloria Paul\\n   - **Date of Birth:** July 15, 1944     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Age: 79)\\n   - **Gender:** Other\\n   - **Medical Condition:** Hyperlipidemia\\n   - **Medications:** Currently  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ taking Atorvastatin\\n   - **Allergies:** None\\n   - **Blood Type:** O+\\n   - **Last Visit Date:** March 26,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2024\\n   - **Smoking Status:** Never Smoker\\n   - **Alcohol Consumption:** Light drinker (1-2 times a week)\\n   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ - **Occupation:** Administrator (sports)\\n   - **Height:** 176.2 cm\\n   - **Weight:** 77.7 kg\\n   - **Blood     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Pressure:** 120/79 mmHg\\n   - **Heart Rate:** 90 bpm\\n   - **Notes:** No significant recent notes were          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provided.\\n\\n2. **ACC Guidelines on Hyperlipidemia:**\\n   - **Statin Therapy Recommendations:**\\n     - **Class │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ I:** Treatment with statin medications is recommended for all patients with extracranial carotid or vertebral   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ atherosclerosis to reduce LDL cholesterol levels below 100 mg/dL. \\n     - **Class IIa:** It is reasonable for  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with ischemic strokes to have their LDL-cholesterol reduced to levels near or below 70 mg/dL.\\n     -  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ If LDL levels remain inadequately controlled on maximally tolerated statin doses, intensifying therapy with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ additional drugs such as bile acid sequestrants or niacin is recommended.\\n     - **Non-statin Options:** For   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients who cannot tolerate statins, LDL-lowering therapy with non-statin options like bile acid sequestrants  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or niacin is appropriate.\\n\\n3. **FDA Medication Updates (February 2025):**\\n   - No specific new medication    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ updates related to hyperlipidemia were found as of February 2025.\\n\\n### Conclusion:\\nGloria Paul has a medical │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ history of hyperlipidemia and is currently treated with Atorvastatin, in line with ACC guidelines that          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommend statin therapy for such patients. There were no new FDA updates to report regarding medications for   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia as of February 2025. It is advised to monitor her LDL levels regularly and adjust treatment if   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ needed, considering adherence to the current therapy.', refusal=None, role='assistant', audio=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function_call=None, tool_calls=None)                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='### Summary of Findings for Gloria \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPaul:\\n\\n1. **Patient Medical Details:**\\n   - **Name:** Gloria Paul\\n   - **Date of Birth:** July 15, 1944 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Age: 79)\\n   - **Gender:** Other\\n   - **Medical Condition:** Hyperlipidemia\\n   - **Medications:** Currently \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtaking Atorvastatin\\n   - **Allergies:** None\\n   - **Blood Type:** O+\\n   - **Last Visit Date:** March 26, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2024\\n   - **Smoking Status:** Never Smoker\\n   - **Alcohol Consumption:** Light drinker (1-2 times a week)\\n  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m- **Occupation:** Administrator (sports)\\n   - **Height:** 176.2 cm\\n   - **Weight:** 77.7 kg\\n   - **Blood \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPressure:** 120/79 mmHg\\n   - **Heart Rate:** 90 bpm\\n   - **Notes:** No significant recent notes were \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovided.\\n\\n2. **ACC Guidelines on Hyperlipidemia:**\\n   - **Statin Therapy Recommendations:**\\n     - **Class\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mI:** Treatment with statin medications is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2matherosclerosis to reduce LDL cholesterol levels below 100 mg/dL. \\n     - **Class IIa:** It is reasonable for \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with ischemic strokes to have their LDL-cholesterol reduced to levels near or below 70 mg/dL.\\n     - \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIf LDL levels remain inadequately controlled on maximally tolerated statin doses, intensifying therapy with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madditional drugs such as bile acid sequestrants or niacin is recommended.\\n     - **Non-statin Options:** For \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients who cannot tolerate statins, LDL-lowering therapy with non-statin options like bile acid sequestrants \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor niacin is appropriate.\\n\\n3. **FDA Medication Updates (February 2025):**\\n   - No specific new medication \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mupdates related to hyperlipidemia were found as of February 2025.\\n\\n### Conclusion:\\nGloria Paul has a medical\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhistory of hyperlipidemia and is currently treated with Atorvastatin, in line with ACC guidelines that \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommend statin therapy for such patients. There were no new FDA updates to report regarding medications for \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia as of February 2025. It is advised to monitor her LDL levels regularly and adjust treatment if \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mneeded, considering adherence to the current therapy.', refusal=None, role='assistant', audio=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction_call=None, tool_calls=None)\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Summary of Findings for Gloria Paul:                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Patient Medical Details:**                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Name:** Gloria Paul                                                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Date of Birth:** July 15, 1944 (Age: 79)                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Gender:** Other                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Medical Condition:** Hyperlipidemia                                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Medications:** Currently taking Atorvastatin                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Allergies:** None                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Blood Type:** O+                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Last Visit Date:** March 26, 2024                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Smoking Status:** Never Smoker                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Alcohol Consumption:** Light drinker (1-2 times a week)                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Occupation:** Administrator (sports)                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Height:** 176.2 cm                                                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Weight:** 77.7 kg                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Blood Pressure:** 120/79 mmHg                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Heart Rate:** 90 bpm                                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Notes:** No significant recent notes were provided.                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **ACC Guidelines on Hyperlipidemia:**                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Statin Therapy Recommendations:**                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">      - **Class I:** Treatment with statin medications is recommended for all patients with extracranial carotid </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> or vertebral atherosclerosis to reduce LDL cholesterol levels below 100 mg/dL.                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">      - **Class IIa:** It is reasonable for patients with ischemic strokes to have their LDL-cholesterol reduced </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> to levels near or below 70 mg/dL.                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">      - If LDL levels remain inadequately controlled on maximally tolerated statin doses, intensifying therapy   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> with additional drugs such as bile acid sequestrants or niacin is recommended.                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">      - **Non-statin Options:** For patients who cannot tolerate statins, LDL-lowering therapy with non-statin   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> options like bile acid sequestrants or niacin is appropriate.                                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **FDA Medication Updates (February 2025):**                                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - No specific new medication updates related to hyperlipidemia were found as of February 2025.               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Conclusion:                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Gloria Paul has a medical history of hyperlipidemia and is currently treated with Atorvastatin, in line with    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ACC guidelines that recommend statin therapy for such patients. There were no new FDA updates to report         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> regarding medications for hyperlipidemia as of February 2025. It is advised to monitor her LDL levels regularly </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> and adjust treatment if needed, considering adherence to the current therapy.                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Summary of Findings for Gloria Paul:\u001b[0m\u001b[1;32m                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Patient Medical Details:**\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Name:** Gloria Paul\u001b[0m\u001b[1;32m                                                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Date of Birth:** July 15, 1944 (Age: 79)\u001b[0m\u001b[1;32m                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Gender:** Other\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Medical Condition:** Hyperlipidemia\u001b[0m\u001b[1;32m                                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Medications:** Currently taking Atorvastatin\u001b[0m\u001b[1;32m                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Allergies:** None\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Blood Type:** O+\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Last Visit Date:** March 26, 2024\u001b[0m\u001b[1;32m                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Smoking Status:** Never Smoker\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Alcohol Consumption:** Light drinker (1-2 times a week)\u001b[0m\u001b[1;32m                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Occupation:** Administrator (sports)\u001b[0m\u001b[1;32m                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Height:** 176.2 cm\u001b[0m\u001b[1;32m                                                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Weight:** 77.7 kg\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Blood Pressure:** 120/79 mmHg\u001b[0m\u001b[1;32m                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Heart Rate:** 90 bpm\u001b[0m\u001b[1;32m                                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Notes:** No significant recent notes were provided.\u001b[0m\u001b[1;32m                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **ACC Guidelines on Hyperlipidemia:**\u001b[0m\u001b[1;32m                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Statin Therapy Recommendations:**\u001b[0m\u001b[1;32m                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m     - **Class I:** Treatment with statin medications is recommended for all patients with extracranial carotid\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mor vertebral atherosclerosis to reduce LDL cholesterol levels below 100 mg/dL. \u001b[0m\u001b[1;32m                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m     - **Class IIa:** It is reasonable for patients with ischemic strokes to have their LDL-cholesterol reduced\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mto levels near or below 70 mg/dL.\u001b[0m\u001b[1;32m                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m     - If LDL levels remain inadequately controlled on maximally tolerated statin doses, intensifying therapy \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mwith additional drugs such as bile acid sequestrants or niacin is recommended.\u001b[0m\u001b[1;32m                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m     - **Non-statin Options:** For patients who cannot tolerate statins, LDL-lowering therapy with non-statin \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32moptions like bile acid sequestrants or niacin is appropriate.\u001b[0m\u001b[1;32m                                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **FDA Medication Updates (February 2025):**\u001b[0m\u001b[1;32m                                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - No specific new medication updates related to hyperlipidemia were found as of February 2025.\u001b[0m\u001b[1;32m              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Conclusion:\u001b[0m\u001b[1;32m                                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGloria Paul has a medical history of hyperlipidemia and is currently treated with Atorvastatin, in line with \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mACC guidelines that recommend statin therapy for such patients. There were no new FDA updates to report \u001b[0m\u001b[1;32m       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mregarding medications for hyperlipidemia as of February 2025. It is advised to monitor her LDL levels regularly\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mand adjust treatment if needed, considering adherence to the current therapy.\u001b[0m\u001b[1;32m                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "run_multi_step_agent(\"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
